KDR and acute myeloblastic leukemia with maturation: Based on these studies and our promising preclinical data, we recommend conducting a case series where patients with AM are treated with ICI and Lenvatinib, or another regionally available dual FGFR/VEGFR inhibitor, as a second- or third-line therapy to further establish clinical benefit.